Latanoprost

Spezifikationen

130209-82-4CAS-Nummer

634-172-9EG-Nummer

propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoateIUPAC-Name

C26H40O5Chemische Formel

432.6 g/molMolekulargewicht

latanoprost; 130209-82-4; Xalatan; PhXA41; PHXA-41; XA41; PhXA 41; XA-41; IYUZEH; latanoprost (isopropyl ester); latanoprostum; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; 6Z5B6HVF6O; XELPROS; DTXSID1041057; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; T-2345; CHEBI:6384; propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate; T2345; XALACOM COMPONENT LATANOPROST; propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Latanoprost PF; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-; Monopost; isopropyl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate; propan-2-yl (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate; propan-2-yl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate; RefChem:58147; DTXCID9021057; S01EE01; Latanoprost Ophthalmic Solution 0.005%; 634-172-9; Latanoprost CRS; Latanoprost, (+/-)-; 8S5FB3XXG8; (Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate; C26H40O5; MFCD00216074; isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; (15R)-Latanoprost; Catioprost; 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester; SMR000466354; Xalatan (TN); UNII-6Z5B6HVF6O; Nova-21027; Latanoprost [USAN:INN:BAN]; Latanoprost?; XA 41; 155551-81-8; PhXA34 [as 15(R,S)-isomer]; AR-202; Latanoprost (Standard); L-PPDS; LATANOPROST [MI]; LATANOPROST [INN]; LATANOPROST [JAN]; LATANOPROST [USAN]; UNII-8S5FB3XXG8; LATANOPROST [VANDF]; CHEMBL1051; LATANOPROST [MART.]; SCHEMBL24698; LATANOPROST [USP-RS]; LATANOPROST [WHO-DD]; MLS000759468; MLS001424106; Latanoprost (JAN/USP/INN); GTPL1961; orb1305354; HY-B0577R; LATANOPROST [ORANGE BOOK]; HMS2051H11; HMS2089J17; HMS3715N22; LATANOPROST [EP MONOGRAPH]; LATANOPROST [USP MONOGRAPH]; EX-A1770; HY-B0577; MSK15025; BDBM50240648; EBC-27082; s4709; ROCKLATAN COMPONENT LATANOPROST; AKOS024458331; CCG-100946; DB00654; FL24849; NC00196; NCGC00246969-01; NCGC00246969-06; AS-75099; Isopropyl-(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate; L0262; D00356; AB00640005-04; AB00640005-06; EN300-21692769; F861701; Q634959; SR-01000759428; SR-01000759428-4; BRD-K10961822-001-05-1; Latanoprost Working Standard (Secondary Reference Standard); Latanoprost, United States Pharmacopeia (USP) Reference Standard; (1R,2R,3R,5S,3''R)-7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic acid isopropyl ester; 5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))-; Isopropyl (5Z,9| inverted exclamation mark,11| inverted exclamation mark,15R)-9,11,15-Trihydroxy-17-Phenyl-18,19,20-Trinor-Prost-5-En-1-Oate; Isopropyl (5Z,9|?,11|?,15R)-9,11,15-Trihydroxy-17-Phenyl-18,19,20-Trinor-Prost-5-En-1-Oate; isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate; isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenyl-pentyl]cyclopentyl]hept-5-enoateSynonyme